VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

ADXS11-001
Vaccine Information
  • Vaccine Name: ADXS11-001
  • Target Pathogen: Human Papillomavirus
  • Target Disease: HPV infection
  • Product Name: Neoadjuvant ADXS11-001 (ADXS-HPV)
  • Manufacturer: Advaxis
  • Type: Live, attenuated vaccine
  • Status: Clinical trial
  • Host Species for Licensed Use: Human
  • Antigen: (Galicia-Carmona et al., 2021)Antigen presenting cell alert the adaptive immune response of the presence of Lm through the major
    histocompatibility complex (MHC) molecules by two different routes. LM antigens from bacteria. tumor antigen-specific cytotoxic CD8
  • E7 Type 16 gene engineering:
    • Type: Recombinant protein preparation
    • Description: The tumor-associated antigen (HPV16 E7) is expressed via live attenuated Listeria monocytogenes-listeriolysin O (Lm-LLO), which helped stimulate the antigen-specific immune responses (Galicia-Carmona et al., 2021).
    • Detailed Gene Information: Click Here.
  • Preparation: (Galicia-Carmona et al., 2021)They prepared two recombinant Lm strains, one expressing the HPV-16 E7 protein without attempting to modify the LLO molecule (Lm-E7), and the second expressed E7 as a non-hemolytic LLO-bound fusion protein (Lm-LLO-E7).
  • Immunization Route: Intravenous injection (i.v.)
  • Approved Age for Licensed Use: (Galicia-Carmona et al., 2021)18 Years and older
  • Description: (Galicia-Carmona et al., 2021) LM based vectors infect antigen presenting cells and secrete HPV-LLO fusion proteins with the APC cytoplasm. These proteins are processed and presented to cytotoxic T lymphocytes (CTL), thus generating a new population of CTLs specific to HPV antigens. These HPV-specific CTLs destroy HPV infected cells.
Host Response
References
Galicia-Carmona et al., 2021: Galicia-Carmona T, Arango-Bravo E, Serrano-Olvera JA, Flores-de La Torre C, Cruz-Esquivel I, Villalobos-Valencia R, Morán-Mendoza A, Castro-Eguiluz D, Cetina-Pérez L. ADXS11-001 LM-LLO as specific immunotherapy in cervical cancer. Human vaccines & immunotherapeutics. 2021; 17(8); 2617-2625. [PubMed: 33793380].